{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:18:04Z","timestamp":1793395084932,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11864-025-01355-z","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:03:27Z","timestamp":1758884607000},"page":"929-942","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Advancing Bladder Cancer Management: The Role of Neoadjuvant and Adjuvant Therapies and Biomarkers in Muscle Invasive Bladder Cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Lingbin","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Khorasanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"1355_CR1","unstructured":"Key Statistics for Bladder Cancer [Internet]. [cited 2025 Mar 19]. Available from: https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/about\/key-statistics.html"},{"issue":"3","key":"1355_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4111\/icu.20230006","volume":"64","author":"KH Kim","year":"2023","unstructured":"Kim KH, Lee HW, Ha HK, Seo HK. Perioperative systemic therapy in muscle invasive bladder cancer: current standard method, biomarkers and emerging strategies. Investig Clin Urol. 2023;64(3):202\u201318.","journal-title":"Investig Clin Urol"},{"issue":"9","key":"1355_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u201366.","journal-title":"N Engl J Med"},{"issue":"9373","key":"1355_CR4","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","volume":"361","author":"Advanced Bladder Cancer Meta-analysis Collaboration","year":"2003","unstructured":"Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361(9373):1927\u201334.","journal-title":"Lancet"},{"issue":"1","key":"1355_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.eururo.2012.08.010","volume":"63","author":"CN Sternberg","year":"2013","unstructured":"Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI. International consultation on urologic Disease-European association of urology consultation on bladder cancer 2012. ICUD-EAU international consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013;63(1):58\u201366.","journal-title":"Eur Urol"},{"issue":"18","key":"1355_CR6","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","volume":"32","author":"ER Plimack","year":"2014","unstructured":"Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014;32(18):1895\u2013901.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1355_CR7","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer unfit for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1355_CR8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.6004\/jnccn.2018.0072","volume":"16","author":"TW Flaig","year":"2018","unstructured":"Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN guidelines insights: bladder cancer, version 5.2018. J Natl Compr Canc Netw. 2018;16(9):1041\u201353.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1355_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","volume":"16","author":"CN Sternberg","year":"2015","unstructured":"Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N\u2009+\u2009M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(1):76\u201386.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1355_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1464-410X.2006.05859.x","volume":"97","author":"J Lehmann","year":"2006","unstructured":"Lehmann J, Franzaring L, Th\u00fcroff J, Wellek S, St\u00f6ckle M. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int. 2006;97(1):42\u20137.","journal-title":"BJU Int"},{"issue":"11","key":"1355_CR11","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"12","key":"1355_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335.","journal-title":"N Engl J Med"},{"issue":"4","key":"1355_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucian\u00f2 R, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77(4):439\u201346.","journal-title":"Eur Urol"},{"issue":"22","key":"1355_CR14","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102\u201314.","journal-title":"N Engl J Med"},{"issue":"1","key":"1355_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med. 2025;392(1):45\u201355.","journal-title":"N Engl J Med"},{"issue":"4","key":"1355_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O\u2019Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T. IMvigor010 study group. Adjuvant Atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):525\u201337.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1355_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2217\/fon-2022-0868","volume":"19","author":"F Jackson-Spence","year":"2023","unstructured":"Jackson-Spence F, Toms C, O\u2019Mahony LF, Choy J, Flanders L, Szabados B, Powles T. IMvigor011: a study of adjuvant Atezolizumab in patients with high-risk MIBC who are ctDNA\u2009+\u2009post-surgery. Future Oncol. 2023;19(7):509\u201315.","journal-title":"Future Oncol"},{"issue":"10","key":"1355_CR18","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O\u2019Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, Bahl S, Gupta N, Farlow D, Qu A, Signoretti S, Barletta JA, Reuter V, Boehm J, Lawrence M, Getz G, Kantoff P, Bochner BH, Choueiri TK, Bajorin DF, Solit DB, Gabriel S, D\u2019Andrea A, Garraway LA, Rosenberg JE. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014;4(10):1140\u201353.","journal-title":"Cancer Discov"},{"issue":"2","key":"1355_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","volume":"18","author":"DM Jiang","year":"2021","unstructured":"Jiang DM, Gupta S, Kitchlu A, Meraz-Munoz A, North SA, Alimohamed NS, Blais N, Sridhar SS. Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nat Rev Urol. 2021;18(2):104\u201314.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1355_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.euo.2018.09.004","volume":"2","author":"L Boeri","year":"2019","unstructured":"Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, et al. Delaying radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer is associated with adverse survival outcomes. Eur Urol Oncol. 2019;2(4):390\u20136.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"1355_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/JU.0000000000001325","volume":"205","author":"A Hajiran","year":"2021","unstructured":"Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, et al. Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without neoadjuvant chemotherapy. J Urol. 2021;205(1):100\u20138.","journal-title":"J Urol"},{"issue":"11","key":"1355_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrurol.2017.125","volume":"14","author":"M Moschini","year":"2017","unstructured":"Moschini M, D\u2019Andrea D, Korn S, Irmak Y, Soria F, Comp\u00e9rat E, Shariat SF. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol. 2017;14(11):651\u201368.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"1355_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","volume":"81","author":"G Sj\u00f6dahl","year":"2022","unstructured":"Sj\u00f6dahl G, Abrahamsson J, Holmsten K, Bernardo C, Chebil G, Eriksson P, et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. 2022;81(5):523\u201332.","journal-title":"Eur Urol"},{"issue":"1","key":"1355_CR24","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","volume":"11","author":"A Taber","year":"2020","unstructured":"Taber A, Christensen E, Lamy P, Nordentoft I, Prip F, Lindskrog SV, Birkenkamp-Demtr\u00f6der K, Okholm TLH, Knudsen M, Pedersen JS, Steiniche T, Agerb\u00e6k M, Jensen JB, Dyrskj\u00f8t L. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat Commun. 2020;11(1):4858.","journal-title":"Nat Commun"},{"key":"1355_CR25","unstructured":"Sternberg A. Monitoring of ctDNA in Patients With Bladder Cancer Has Potential to Assist Therapy Selection. 2019 Jun 19 [cited 2025 Mar 20];8. Available from: https:\/\/www.targetedonc.com\/view\/monitoring-of-ctdna-in-patients-with-bladder-cancer-has-potential-to-assist-therapy-selection"},{"issue":"8","key":"1355_CR26","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","volume":"29","author":"E Christensen","year":"2023","unstructured":"Christensen E, Nordentoft I, Birkenkamp-Demtr\u00f6der K, Elb\u00e6k SK, Lindskrog SV, Taber A, et al. Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer. Clin Cancer Res. 2023;29(8):1582\u201391.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"1355_CR27","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","volume":"23","author":"G Vandekerkhove","year":"2017","unstructured":"Vandekerkhove G, Todenh\u00f6fer T, Annala M, Struss WJ, Wong A, Beja K, et al. Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer. Clin Cancer Res. 2017;23(21):6487\u201397.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1355_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","volume":"71","author":"E Christensen","year":"2017","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Nordentoft I, H\u00f8yer S, van der Keur K, van Kessel K, et al. Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur Urol. 2017;71(6):961\u20139.","journal-title":"Eur Urol"},{"issue":"1","key":"1355_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","volume":"70","author":"K Birkenkamp-Demtr\u00f6der","year":"2016","unstructured":"Birkenkamp-Demtr\u00f6der K, Nordentoft I, Christensen E, H\u00f8yer S, Reinert T, Vang S, Borre M, Agerb\u00e6k M, Jensen JB, \u00d8rntoft TF, Dyrskj\u00f8t L. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol. 2016;70(1):75\u201382.","journal-title":"Eur Urol"},{"issue":"10","key":"1355_CR30","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/cncr.31314","volume":"124","author":"N Agarwal","year":"2018","unstructured":"Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, et al. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018;124(10):2115\u201324.","journal-title":"Cancer"},{"issue":"9","key":"1355_CR31","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167\u201377.","journal-title":"Ann Oncol"},{"issue":"23","key":"1355_CR32","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","volume":"29","author":"SV Lindskrog","year":"2023","unstructured":"Lindskrog SV, Birkenkamp-Demtr\u00f6der K, Nordentoft I, Laliotis G, Lamy P, Christensen E, et al. Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up. Clin Cancer Res. 2023;29(23):4797\u2013807.","journal-title":"Clin Cancer Res"},{"key":"1355_CR33","unstructured":"ASCO GU 2024: Predictive Value of Dynamic Changes in ctDNA and Baseline Biomarkers with Neoadjuvant Atezolizumab in Operable Urothelial Carcinoma in the ABACUS Trial [Internet]. [cited 2025 Mar 20]. Available from: https:\/\/www.urotoday.com\/conference-highlights\/asco-gu-2024\/asco-gu-2024-bladder-cancer\/149391-asco-gu-2024-predictive-value-of-dynamic-changes-in-ctdna-and-baseline-biomarkers-with-neoadjuvant-atezolizumab-in-operable-urothelial-carcinoma-in-the-abacus-trial.html"},{"issue":"4","key":"1355_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","volume":"9","author":"JC Dudley","year":"2019","unstructured":"Dudley JC, Schroers-Martin J, Lazzareschi DV, Shi WY, Chen SB, Esfahani MS, et al. Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discov. 2019;9(4):500\u20139.","journal-title":"Cancer Discov"},{"issue":"1","key":"1355_CR35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, Sun T, Wei J. Liquid biopsy in cancer: current status, challenges and future prospects. Sig Transduct Target Ther. 2024;9(1):336.","journal-title":"Sig Transduct Target Ther"},{"issue":"9","key":"1355_CR36","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1158\/1541-7786.MCR-17-0070","volume":"15","author":"RG Gupta","year":"2017","unstructured":"Gupta RG, Somer RA. Intratumor heterogeneity: novel approaches for resolving genomic architecture and clonal evolution. Mol Cancer Res. 2017;15(9):1127\u201337.","journal-title":"Mol Cancer Res"},{"issue":"13","key":"1355_CR37","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-19-3015","volume":"26","author":"SR Greytak","year":"2020","unstructured":"Greytak SR, Engel KB, Parpart-Li S, Murtaza M, Bronkhorst AJ, Pertile MD, et al. Harmonizing cell-free DNA collection and processing practices through evidence-based guidance. Clin Cancer Res. 2020;26(13):3104\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1355_CR38","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666\u201375.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1355_CR39","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1464-410X.2010.09912.x","volume":"108","author":"FA Yafi","year":"2011","unstructured":"Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int. 2011;108(4):539\u201345.","journal-title":"BJU Int"},{"issue":"18","key":"1355_CR40","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1002\/cncr.24466","volume":"115","author":"G Sonpavde","year":"2009","unstructured":"Sonpavde G, Goldman BH, Speights VO, Lerner SP, Wood DP, Vogelzang NJ, Trump DL, Natale RB, Grossman HB, Crawford ED. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009;115(18):4104\u20139.","journal-title":"Cancer"},{"issue":"3","key":"1355_CR41","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0022-5347(17)37318-4","volume":"147","author":"TA Splinter","year":"1992","unstructured":"Splinter TA, Scher HI, Denis L, Bukowski R, Simon S, Klimberg I, Soloway M, Vogelzang NJ, van Tinteren H, Herr H. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European organization for research on treatment of Cancer\u2013Genitourinary group. J Urol. 1992;147(3):606\u20138.","journal-title":"J Urol"},{"issue":"10","key":"1355_CR42","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"CN Sternberg","year":"2001","unstructured":"Sternberg CN, de Mulder PH, Schornagel JH, Th\u00e9odore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de Balincourt C, Collette L, European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and Recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol 30924. J Clin Oncol. 2001;19(10):2638\u201346.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1355_CR43","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/s41598-024-51273-7","volume":"14","author":"D Ikarashi","year":"2024","unstructured":"Ikarashi D, Kitano S, Tsuyukubo T, Yamashita M, Matsuura T, Maekawa S, et al. Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer. Sci Rep. 2024;14(1):1442.","journal-title":"Sci Rep"},{"issue":"1","key":"1355_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010168","volume":"15","author":"H Miyagi","year":"2022","unstructured":"Miyagi H, Kwenda E, Ramnaraign BH, Chatzkel JA, Brisbane WG, O\u2019Malley P, et al. Predicting complete response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Cancers (Basel). 2022;15(1):168.","journal-title":"Cancers (Basel)"},{"key":"1355_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.912699","volume":"12","author":"G Roviello","year":"2022","unstructured":"Roviello G, Catalano M, Santi R, Santoni M, Galli IC, Amorosi A, et al. Neoadjuvant treatment in Muscle-invasive bladder cancer: from the beginning to the latest developments. Front Oncol. 2022;12:912699.","journal-title":"Front Oncol"},{"key":"1355_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.urology.2024.04.034","volume":"188","author":"CJ Eule","year":"2024","unstructured":"Eule CJ, Warren A, Molina Kuna E, Callihan EB, Kim SP, Flaig TW. Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: a systematic review and pooled meta-analysis to determine the preferred regimen. Urology. 2024;188:118\u201324.","journal-title":"Urology"},{"issue":"6","key":"1355_CR47","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.juro.2017.12.062","volume":"199","author":"H Zargar","year":"2018","unstructured":"Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, et al. Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with ct3-4an0m0 bladder cancer treated with radical cystectomy. J Urol. 2018;199(6):1452\u20138.","journal-title":"J Urol"},{"issue":"2","key":"1355_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"C Pfister","year":"2021","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, Souli\u00e9 M, Guy L, Laguerre B, et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG\/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol. 2021;79(2):214\u201321.","journal-title":"Eur Urol"},{"issue":"18","key":"1355_CR49","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.21.02051","volume":"40","author":"C Pfister","year":"2022","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, Chevreau C, Mahammedi H, Laguerre B, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol. 2022;40(18):2013\u201322.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1355_CR50","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","volume":"27","author":"TW Flaig","year":"2021","unstructured":"Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021;27(9):2435\u201341.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1355_CR51","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi A, Raggi D, Gallina A, Ross JS, Far\u00e8 E, Giannatempo P, et al. Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur Urol. 2020;77(6):701\u201310.","journal-title":"Eur Urol"},{"issue":"23","key":"1355_CR52","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","volume":"28","author":"G Basile","year":"2022","unstructured":"Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, Costa de Padua T, Crupi E, Colombo R, Colecchia M, Lucian\u00f2 R, Nocera L, Moschini M, Briganti A, Montorsi F, Necchi A. Neoadjuvant pembrolizumab and radical cystectomy in patients with Muscle-Invasive urothelial bladder cancer: 3-Year median Follow-Up update of PURE-01 trial. Clin Cancer Res. 2022;28(23):5107\u201314.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1355_CR53","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022;82(2):212\u201322.","journal-title":"Eur Urol"},{"issue":"12","key":"1355_CR54","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, van Montfoort ML, van Rooijen C, Peters D, Broeks A, van der Poel HG, Bruining A, Lubeck Y, Sikorska K, Boellaard TN, Kvistborg P, Vis DJ, Hooijberg E, Schumacher TN, van den Broek M, Wessels LFA, Blank CU, van Rhijn BW, van der Heijden MS. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26(12):1839\u201344.","journal-title":"Nat Med"},{"issue":"12","key":"1355_CR55","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","volume":"26","author":"J Gao","year":"2020","unstructured":"Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020;26(12):1845\u201351.","journal-title":"Nat Med"},{"issue":"15suppl","key":"1355_CR56","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1200\/JCO.2021.39.15_suppl.4518","volume":"39","author":"P Grivas","year":"2021","unstructured":"Grivas P, Yin J, Koshkin VS, Cole S, Jain RK, Dreicer R, et al. PrE0807: a phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). JCO. 2021;39(15suppl):4518\u20134518.","journal-title":"JCO"},{"issue":"16suppl","key":"1355_CR57","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1200\/JCO.2022.40.16_suppl.4517","volume":"40","author":"N Martinez Chanza","year":"2022","unstructured":"Martinez Chanza N, Carnot A, Barth\u00e9l\u00e9my P, Casert V, Staudacher L, Van Den Brande J, et al. Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial. JCO. 2022;40(16suppl):4517\u20134517.","journal-title":"JCO"},{"issue":"12","key":"1355_CR58","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.21.01485","volume":"40","author":"SA Funt","year":"2022","unstructured":"Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with Muscle-Invasive bladder cancer: a multicenter, single-arm, phase II trial. J Clin Oncol. 2022;40(12):1312\u201322.","journal-title":"J Clin Oncol"},{"issue":"6suppl","key":"1355_CR59","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1200\/JCO.2023.41.6_suppl.448","volume":"41","author":"J Brown","year":"2023","unstructured":"Brown J, Kaimakliotis HZ, Kelly WK, Ammons V, Picus J, Walling R, Hashemi-Sadraei N, Fu P, Margevicius SP, Adra N, Garcia JA, McKay RR, Hoimes CJ. HCRN GU14-188: phase ib\/ii study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer. JCO. 2023;41(6suppl):448\u2013448.","journal-title":"JCO"},{"issue":"11","key":"1355_CR60","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D\u2019Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2023;29(11):2825\u201334.","journal-title":"Nat Med"},{"issue":"6suppl","key":"1355_CR61","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1200\/JCO.2020.38.6_suppl.499","volume":"38","author":"R Cathomas","year":"2020","unstructured":"Cathomas R, Petrausch U, Hayoz S, Schneider M, Schardt JA, Seiler R, et al. Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin\/gemcitabine (Cis\/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): preplanned interim analysis of a single-arm phase II trial (SAKK 06\/17). JCO. 2020;38(6suppl):499\u2013499.","journal-title":"JCO"},{"issue":"19","key":"1355_CR62","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024;391(19):1773\u201386.","journal-title":"N Engl J Med"},{"issue":"16suppl","key":"1355_CR63","doi-asserted-by":"publisher","first-page":"TPS4623","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4623","volume":"42","author":"SA Hussain","year":"2024","unstructured":"Hussain SA, Loriot Y, De Velasco G, Necchi A, SOGUG-NEOWIN:. A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations. JCO. 2024;42(16suppl):TPS4623\u20134623.","journal-title":"JCO"},{"issue":"16suppl","key":"1355_CR64","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1200\/JCO.2024.42.16_suppl.4568","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng X, Yang K, Ji Y, Zhou L, Zou B, Huang H, et al. Preliminary efficacy and safety results from RC48-C017: a phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression. JCO. 2024;42(16suppl):4568\u20134568.","journal-title":"JCO"},{"issue":"6suppl","key":"1355_CR65","doi-asserted-by":"publisher","first-page":"TPS588","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS588","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Loriot Y, Bedke J, Nishiyama H, Kataria RS, Homet Moreno B, Galsky MD. Perioperative enfortumab Vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): phase 3 KEYNOTE-B15\/EV-304. JCO. 2023;41(6suppl):TPS588\u2013588.","journal-title":"JCO"},{"key":"1355_CR66","unstructured":"ESMO 2024. STAR-EV: Stereotactic Treatment with Neoadjuvant Radiotherapy and Enfortumab Vedotin: A Phase I\/II Study for Localized, Cisplatin Ineligible, Muscle Invasive Bladder Cancer [Internet]. [cited 2025 Mar 20]. Available from: https:\/\/www.urotoday.com\/conference-highlights\/esmo-2024\/esmo-2024-bladder-cancer\/154910-esmo-2024-star-ev-stereotactic-treatment-with-neoadjuvant-radiotherapy-and-enfortumab-vedotin-a-phase-i-ii-study-for-localized-cisplatin-ineligible-muscle-invasive-bladder-cancer.html"},{"issue":"6","key":"1355_CR67","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","volume":"68","author":"ER Plimack","year":"2015","unstructured":"Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015;68(6):959\u201367.","journal-title":"Eur Urol"},{"key":"1355_CR68","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ebiom.2018.06.011","volume":"35","author":"Z Yang","year":"2018","unstructured":"Yang Z, Zhang R, Ge Y, Qin X, Kang X, Wang Y, et al. Somatic FGFR3 mutations distinguish a subgroup of muscle-invasive bladder cancers with response to neoadjuvant chemotherapy. EBioMedicine. 2018;35:198\u2013203.","journal-title":"EBioMedicine"},{"issue":"46","key":"1355_CR69","doi-asserted-by":"publisher","first-page":"81204","DOI":"10.18632\/oncotarget.20979","volume":"8","author":"HS Kim","year":"2017","unstructured":"Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials. Oncotarget. 2017;8(46):81204\u201314.","journal-title":"Oncotarget"},{"issue":"9","key":"1355_CR70","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/cncr.31952","volume":"125","author":"S Berg","year":"2019","unstructured":"Berg S, D\u2019Andrea D, Vetterlein MW, Cole AP, Fletcher SA, Krimphove MJ, et al. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: does histologic subtype matter? Cancer. 2019;125(9):1449\u201358.","journal-title":"Cancer"},{"issue":"8","key":"1355_CR71","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JCO.2015.64.1076","volume":"34","author":"MD Galsky","year":"2016","unstructured":"Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol. 2016;34(8):825\u201332.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1355_CR72","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1158\/1078-0432.CCR-10-0457","volume":"16","author":"RS Svatek","year":"2010","unstructured":"Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010;16(17):4461\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1355_CR73","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42\u201354.","journal-title":"Eur Urol"},{"issue":"3","key":"1355_CR74","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0022-5347(17)38368-4","volume":"145","author":"DG Skinner","year":"1991","unstructured":"Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145(3):459\u201364. discussion 464\u2013467.","journal-title":"J Urol"},{"key":"1355_CR75","unstructured":"ASCO 2023: FGFR3 Alterations in PROOF 302: A Phase III Trial of Infigratinib (BGJ398) as Adjuvant Therapy in Patients with Invasive Urothelial Carcinoma [Internet]. [cited 2025 Mar 20]. Available from: https:\/\/www.urotoday.com\/conference-highlights\/asco-2023\/asco-2023-bladder-cancer\/144884-asco-2023-fgfr3-alterations-in-proof-302-a-phase-iii-trial-of-infigratinib-bgj398-as-adjuvant-therapy-in-patients-with-invasive-urothelial-carcinoma.html"},{"issue":"5","key":"1355_CR76","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.euf.2021.11.004","volume":"8","author":"V Fonteyne","year":"2022","unstructured":"Fonteyne V, Dirix P, Van Praet C, Berghen C, Albersen M, Junius S, et al. Adjuvant radiotherapy after radical cystectomy for patients with high-risk muscle-invasive bladder cancer: results of a multicentric phase II trial. Eur Urol Focus. 2022;8(5):1238\u201345.","journal-title":"Eur Urol Focus"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01355-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01355-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01355-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:03:50Z","timestamp":1761293030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01355-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01355-z","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}